Last updated: May 28, 2026

AstraZeneca is running a clinical trial called CALLISTO, testing a drug called AZD7798 in people with Crohn’s disease. AZD7798 is a monoclonal antibody that targets a receptor called CCR9 on a specific subset of immune cells — CCR9+ lymphocytes — that are involved in directing inflammation toward the small intestine.

This is an early-stage trial. There is no published efficacy data yet, and AZD7798 is not approved. What exists is a mechanistic rationale worth understanding, and a trial underway.

The Mechanism

Most people with Crohn’s who’ve been through a few treatment lines are familiar with the broad strokes of how current biologics work: TNF inhibitors (Humira, Remicade, Cimzia) block a molecule that drives systemic inflammation; IL-12/23 inhibitors (Stelara) target a different inflammatory signaling pathway; JAK inhibitors (Rinvoq, Xeljanz) work inside the cell to interrupt signaling more broadly.

AZD7798 is targeting something different: CCR9, a receptor that appears on a specific subtype of T lymphocytes and helps those cells migrate to the small intestine. The hypothesis is that these CCR9+ cells are driving small-intestine inflammation in Crohn’s patients, and that blocking their migration to the gut — rather than broadly suppressing inflammation — might reduce disease activity with a more targeted effect.

The logic is consistent with where IBD research has been heading for years: more selective mechanisms, smaller populations of cells, fewer off-target effects. Whether it actually works that way in clinical practice is what CALLISTO is meant to test.

Who This Would Potentially Help

If the mechanism is correct and the trial shows efficacy, AZD7798 would be positioned for small-intestine Crohn’s disease — particularly patients who haven’t responded to earlier lines of therapy. That matches a real need: there are patients who cycle through TNF inhibitors, IL-23 inhibitors, and integrin antagonists (Entyvio) without achieving remission, and the options thin out quickly after that.

I’ve been on biologics since 2003 — Remicade for 23 years, then Rinvoq after an insurance switch in early 2026. When a new mechanism comes up, my first question is: what’s the population, and does the biology hold in humans? The CCR9 pathway is interesting enough that I follow it, but I’ve seen enough early-stage mechanisms fail in Phase 3 to stay skeptical until there’s data.

What We Don’t Know

The trial is listed as ongoing. As of when this piece was written, there is no published efficacy data from CALLISTO — no remission rates, no endoscopic improvement numbers, no safety signal from a completed trial. The reporting on this drug has been heavy on the mechanistic rationale and the company announcement; the actual trial results aren’t available yet.

A few things that matter and aren’t answered yet:

• What phase is CALLISTO? The published reporting doesn’t clearly specify the phase. That distinction matters — Phase 1 (safety/dosing) versus Phase 2 (early efficacy) versus Phase 3 (pivotal trial) tells you very different things about how close this is to being an option.
• Does CCR9 targeting work in humans the way the mechanism predicts? The biology is plausible, but plausible mechanisms fail in clinical trials regularly. Vedolizumab (Entyvio) works on a related concept — gut-selective immune trafficking — with a different target (integrin α4β7), and it does achieve meaningful efficacy. AZD7798’s CCR9 approach is different enough that you can’t assume the same result.
• What’s the safety profile? More selective mechanisms don’t automatically mean fewer side effects. The trial data will need to show both.

Where This Sits in the Pipeline

AZD7798 is not an approved treatment. It’s a drug in a clinical trial, with a mechanism that makes biological sense, in a company (AstraZeneca) with the resources to run a serious trial program. That’s a reasonable place to be at this stage of development — but it’s still several years and multiple trial phases away from being something a gastroenterologist can prescribe.

If you’re managing Crohn’s now, this doesn’t change your treatment options. If you’re interested in the science of how IBD might be treated differently in the future, the CCR9 pathway is worth tracking.

The source reporting is from TipRanks, which covers company announcements and investor-facing communications. That framing shapes the coverage — company announcements emphasize the positive case for the mechanism. Peer-reviewed trial data, when it’s published, will give a clearer picture.

Nothing here is medical advice. Treatment decisions should be made with your gastroenterologist based on your specific disease and history.